Regeneron Found a Way to Give Back the Muscle Wegovy Took
Regeneron's experimental antibody trevogrumab cut semaglutide-related muscle loss in half, and even appeared to rebuild muscle after patients stopped Wegovy. The data could create an entirely new companion-therapy market alongside blockbuster GLP-1 drugs.
The Ozempic Era's Dirty Secret
Everyone loves talking about how much weight GLP-1 drugs help people lose. Nobody loves talking about what kind of weight they're losing.
When patients take semaglutide (the active ingredient in Wegovy), they shed fat. Great. But they also lose lean body mass, which includes muscle. In the landmark STEP 1 trial, patients lost about 15% of their body weight overall, and roughly 13.2% of their lean body mass went with it. That's not a rounding error. For older adults or anyone already low on muscle, that tradeoff can mean weaker legs, slower walking, and a higher risk of falls.
Think of it like renovating your house by accidentally knocking down a load-bearing wall. Sure, you got rid of some clutter. But now the structure is compromised.
Regeneron thinks it has the fix.
An Antibody That Blocks the Muscle-Shrinking Signal
The company just presented Phase 2 data from its COURAGE trial, and the headline result is striking: an experimental antibody called trevogrumab, given alongside semaglutide, cut muscle loss roughly in half compared to semaglutide alone.
How does it work? Your body naturally produces a protein called myostatin (also known as GDF-8). Myostatin's job is basically to tell your muscles, "That's enough; stop growing." It acts like a brake on muscle development. Trevogrumab blocks that brake, letting muscles hold on to their mass even when the body is burning through calories on a GLP-1 drug.
The COURAGE trial was a two-part, 52-week study. During the first 26 weeks (the weight-loss phase), semaglutide alone caused about 6.5% lean-mass loss. Adding trevogrumab brought that down to roughly 3.3% to 4.7%, depending on the dose. In an MRI analysis of thigh muscles specifically, the 75 mg dose preserved over 70% of the muscle that semaglutide would have otherwise destroyed.
But the most interesting finding came from what happened patients stopped semaglutide.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
after
The Plot Twist: Rebuilding, Not Just Preserving
In one arm of the trial, patients stopped taking semaglutide but kept receiving trevogrumab. Their muscle mass climbed back to approximately baseline levels. In other words, the antibody didn't just slow muscle loss; it appeared to help rebuild what was already gone.
That distinction matters enormously. Preservation is nice. Restoration is a potential game-changer. It suggests trevogrumab could serve as a kind of recovery tool for the millions of patients cycling on and off GLP-1 drugs (which is common, since many people stop these medications within the first year or two).
Regeneron is already planning a new Phase 2 trial focused on older adults with obesity who have decreased muscle mass or strength. That's exactly the population where muscle loss on GLP-1s is most dangerous.
The Triple Combo That Went Too Far
Regeneron didn't stop at trevogrumab alone. The company also tested a triple combination: semaglutide plus trevogrumab plus garetosmab, an antibody that blocks a different muscle-regulation protein called activin A. The idea was that hitting two brakes at once would preserve even more muscle.
On paper, it worked. Lean-mass loss in the triple combo dropped to about 2.0% to 2.1%. But the side effects were brutal. Patients experienced high rates of muscle spasms and discontinuation. Reuters reported that two participants died in the higher-dose trevogrumab/garetosmab arms during the first 26 weeks.
That's a sobering reminder: more isn't always better. The triple approach appears shelved for now, or at least in need of serious dose optimization. Trevogrumab alone, meanwhile, looks like the cleaner path forward.
Wall Street Is Paying Attention
Analysts reacted favorably to the data. Argus upgraded the stock to Buy with an $850 target. The broader consensus sits in the mid-to-high $800s, with most firms calling it a moderate to strong buy.
The enthusiasm isn't just about trevogrumab itself. It's about what trevogrumab represents: the birth of a companion-therapy market for GLP-1 drugs. Wegovy and Zepbound are on track to become some of the best-selling medications in history. If muscle preservation becomes the standard of care alongside those drugs, the add-on market alone could be massive.
Some analysts remain cautious, pointing out that Phase 2 data is preliminary. Regeneron still needs to prove safety and efficacy in larger Phase 3 trials before this becomes a commercial reality.
A Crowded Race to Protect Muscle
Regeneron isn't the only company chasing this opportunity. The competitive landscape for GLP-1 muscle-preservation add-ons is heating up fast.
Bimagrumab (originally from Novartis, with a Versanis heritage) blocks a receptor called ActRII, which sits downstream of both myostatin and activin. It has the most established clinical track record in obesity body composition and is also being tested alongside GLP-1 therapy. Scholar Rock has two candidates in the space: apitegromab and SRK-439, both selective myostatin inhibitors. And Biohaven is running a Phase 2 program with taldefgrobep alfa, another myostatin/activin pathway inhibitor.
No one has reached the finish line yet. None of these drugs are approved for muscle preservation during obesity treatment. The race is still at the "prove it works" stage, not the "fight for market share" stage.
Why This Could Reshape Obesity Medicine
For years, the obesity conversation has been dominated by one question: how much weight can we help people lose? GLP-1 drugs answered that question convincingly. Semaglutide and tirzepatide deliver 15% to 20%+ weight reductions, and the market has responded with $50 billion-plus valuations.
But medicine is starting to ask a better question: what kind of weight are people losing? If a patient drops 40 pounds, and 8 of those pounds are muscle, that's a very different outcome than losing 40 pounds of pure fat. Especially for a 65-year-old whose mobility and independence depend on muscle strength.
Regeneron's data suggests we might not have to choose. Take semaglutide for the fat loss. Add trevogrumab for the muscle protection. Get the benefits without the structural damage.
It's still early. Phase 3 trials need to confirm the safety profile, durability of benefit, and real-world impact on strength and physical function (not just mass on an MRI). But if the science holds up, trevogrumab could become as essential a companion to GLP-1 therapy as a side salad is to a good steak: technically optional, practically mandatory.
Clinical & Regulatory
4 min read
Amgen's $28 Billion Bet on Horizon Just Got a Whole Lot Smarter
Amgen's $27.8 billion Horizon Therapeutics acquisition just delivered its biggest pipeline surprise yet. A fusion protein that blocks immune cell crosstalk passed its first pivotal trial in Sjögren's disease, a condition with zero approved treatments, and the implications for Amgen's autoimmune franchise are massive.
